[BIOSTAR PHARMACEUTICALS, RECEIVES APPROVAL FROM XIANYANG SFDA TO RESTARTLES OF ITS GELPSULE DRUGS XIANYANG, China, August 3, 2012 - Biostar Pharmaceuticals, (NASDAQ GM: BSPM) ("Biostar" or "thempany"), a-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases andnditions, today announced that on July 30, 2012, after a thorough]
[August 6, 2012 VIA EDGAR Kathleen Collins, Accounting Branch Chief Laura Veator, Staff Accountant Division of Corporation Finance 100 F Street, N.E. Re: Ctrip.com International, Ltd. (the Company) Form 20-F for the Fiscal Year Ended December 31, 2011 Filed on March 30, 2012 (the 2011 Form 20-F) (File No. 001-33853) Dear Ms. Collins and Ms. Veator: * * * Form]
[BIOSTAR PHARMACEUTICALS, RECEIVES APPROVAL FROM XIANYANG SFDA TO RESTARTLES OF ITS GELPSULE DRUGS XIANYANG, China, August 3, 2012 - Biostar Pharmaceuticals, (NASDAQ GM: BSPM) ("Biostar" or "thempany"), a-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases andnditions, today announced that on July 30, 2012, after a thorough]
[August 6, 2012 VIA EDGAR Kathleen Collins, Accounting Branch Chief Laura Veator, Staff Accountant Division of Corporation Finance 100 F Street, N.E. Re: Ctrip.com International, Ltd. (the Company) Form 20-F for the Fiscal Year Ended December 31, 2011 Filed on March 30, 2012 (the 2011 Form 20-F) (File No. 001-33853) Dear Ms. Collins and Ms. Veator: * * * Form]
[Item 1 Information Contained in this Form 6-K Report SEASPAN CORPORATION Sai W. Chu Chief Financial Officer REPORT ON FORM 6-K FOR THE QUARTER ENDED JUNE 30, 2012 INDEX PART I FINANCIAL INFORMATION 1 Item 1 Interim Consolidated Financial Statements (Unaudited) 1 Item 2 Managements Discussion and Analysis of Financial Condition and Results of Operations 25]
[Item 1 Information Contained in this Form 6-K Report SEASPAN CORPORATION Sai W. Chu Chief Financial Officer REPORT ON FORM 6-K FOR THE QUARTER ENDED JUNE 30, 2012 INDEX PART I FINANCIAL INFORMATION 1 Item 1 Interim Consolidated Financial Statements (Unaudited) 1 Item 2 Managements Discussion and Analysis of Financial Condition and Results of Operations 25]
